Patrick Yung Chih Wen, M.D.
Co-Author
This page shows the publications co-authored by Patrick Wen and David Reardon.
Connection Strength
15.575
-
Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Cancer. 2018 04 01; 124(7):1438-1448.
Score: 0.740
-
Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment. Nat Rev Neurol. 2016 Feb; 12(2):69-70.
Score: 0.648
-
One size should not fit all: advancing toward personalized glioblastoma therapy. Discov Med. 2015 Jun; 19(107):471-7.
Score: 0.620
-
Glioma in 2014: unravelling tumour heterogeneity-implications for therapy. Nat Rev Clin Oncol. 2015 Feb; 12(2):69-70.
Score: 0.603
-
Targeted therapies: Further delineating bevacizumab's response spectrum. Nat Rev Clin Oncol. 2014 May; 11(5):243-4.
Score: 0.572
-
Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011 Mar; 13(3):353-61.
Score: 0.460
-
A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011 Apr; 13(4):437-46.
Score: 0.459
-
Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme. J Clin Oncol. 2008 May 20; 26(15_suppl):2051.
Score: 0.381
-
Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist. 2006 Feb; 11(2):152-64.
Score: 0.325
-
Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro Oncol. 2022 01 05; 24(1):101-113.
Score: 0.245
-
Clinical utility of targeted next generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. Neuro Oncol. 2021 Dec 08.
Score: 0.244
-
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin Cancer Res. 2021 02 15; 27(4):1048-1057.
Score: 0.226
-
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020 08 17; 22(8):1073-1113.
Score: 0.222
-
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro Oncol. 2020 05 15; 22(5):601-612.
Score: 0.218
-
Barriers to accrual and enrollment in brain tumor trials. Neuro Oncol. 2019 09 06; 21(9):1100-1117.
Score: 0.208
-
Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery. 2019 09 01; 85(3):E607-E608.
Score: 0.208
-
Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. Cancer Med. 2019 10; 8(13):5988-5994.
Score: 0.208
-
A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. Clin Cancer Res. 2019 10 01; 25(19):5799-5807.
Score: 0.206
-
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750.
Score: 0.200
-
Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2019 01 01; 21(1):26-36.
Score: 0.199
-
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239.
Score: 0.198
-
Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. JCO Precis Oncol. 2018; 2018.
Score: 0.197
-
PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology. 2018 10 02; 91(14):e1355-e1359.
Score: 0.194
-
Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. Clin Cancer Res. 2018 10 01; 24(19):4643-4649.
Score: 0.192
-
Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2018 06 18; 20(7):897-906.
Score: 0.191
-
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro Oncol. 2018 01 22; 20(2):249-258.
Score: 0.186
-
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro Oncol. 2018 01 22; 20(2):259-267.
Score: 0.186
-
Immunomodulation for glioblastoma. Curr Opin Neurol. 2017 06; 30(3):361-369.
Score: 0.178
-
Angiogenesis inhibitors in tackling recurrent glioblastoma. Expert Rev Anticancer Ther. 2017 Jun; 17(6):507-515.
Score: 0.177
-
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol. 2017 05 01; 19(5):625-635.
Score: 0.177
-
A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro Oncol. 2016 06; 18(6):849-54.
Score: 0.163
-
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Cancer. 2016 Feb 15; 122(4):582-7.
Score: 0.160
-
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016 Feb; 4(2):124-35.
Score: 0.160
-
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov; 16(15):e534-e542.
Score: 0.160
-
The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clin Cancer Res. 2016 Feb 01; 22(3):575-81.
Score: 0.159
-
How treatment monitoring is influencing treatment decisions in glioblastomas. Curr Treat Options Neurol. 2015 Apr; 17(4):343.
Score: 0.153
-
Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response. Front Neurol. 2015; 6:33.
Score: 0.152
-
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol. 2015 Jun; 17(6):862-7.
Score: 0.151
-
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20; 84(3):280-6.
Score: 0.150
-
Medical management of brain tumors and the sequelae of treatment. Neuro Oncol. 2015 Apr; 17(4):488-504.
Score: 0.149
-
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol. 2015 Jan; 121(2):297-302.
Score: 0.149
-
Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol. 2014 Oct; 16 Suppl 8:viii7-13.
Score: 0.148
-
Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol. 2014 Oct; 16 Suppl 7:vii36-47.
Score: 0.148
-
Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies. Cancer. 2015 Apr 01; 121(7):997-1007.
Score: 0.148
-
Immunotherapy advances for glioblastoma. Neuro Oncol. 2014 Nov; 16(11):1441-58.
Score: 0.147
-
Phase ii trial of the phosphatidyinositol-3 kinase (pi3k) inhibitor buparlisib (bkm120) in recurrent glioblastoma conducted by the ivy foundation early phase clinical trials consortium. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii47.
Score: 0.145
-
Current status of antiangiogenic therapies for glioblastomas. Expert Opin Investig Drugs. 2014 Feb; 23(2):199-210.
Score: 0.140
-
Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer. 2013 Oct 01; 119(19):3479-88.
Score: 0.136
-
Treatment options in newly diagnosed glioblastoma. Curr Treat Options Neurol. 2013 Jun; 15(3):281-8.
Score: 0.135
-
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013 Jun; 12(6):597-615.
Score: 0.135
-
Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opin Emerg Drugs. 2013 Jun; 18(2):137-53.
Score: 0.134
-
Current and future directions for Phase II trials in high-grade glioma. Expert Rev Neurother. 2013 Apr; 13(4):369-87.
Score: 0.133
-
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res. 2013 Feb 15; 19(4):900-8.
Score: 0.132
-
Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 Jul; 14(7):819-29.
Score: 0.126
-
A novel treatment for glioblastoma: integrin inhibition. Expert Rev Neurother. 2012 Apr; 12(4):421-35.
Score: 0.124
-
Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. Cancer Chemother Pharmacol. 2012 Apr; 69(4):849-60.
Score: 0.121
-
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012 Jan; 106(2):409-15.
Score: 0.120
-
It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol. 2011 Aug 20; 29(24):3211-3.
Score: 0.118
-
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2040.
Score: 0.117
-
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10; 28(11):1963-72.
Score: 0.108
-
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther. 2008 Apr; 8(4):541-53.
Score: 0.094
-
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. Clin Cancer Res. 2022 02 15; 28(4):594-602.
Score: 0.062
-
Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clin Cancer Res. 2022 02 15; 28(4):585-593.
Score: 0.062
-
Combined immunotherapy with controlled Interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: an open-label, multi-institutional phase 1 trial. Neuro Oncol. 2021 Nov 26.
Score: 0.061
-
A Molecularly Integrated Grade for Meningioma. Neuro Oncol. 2021 Sep 11.
Score: 0.060
-
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer. 2021 07; 9(7).
Score: 0.059
-
Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET. Sci Rep. 2021 04 07; 11(1):7632.
Score: 0.058
-
IDH-mutant gliomas with additional class-defining molecular events. Mod Pathol. 2021 07; 34(7):1236-1244.
Score: 0.058
-
Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro Oncol. 2021 03 25; 23(3):356-375.
Score: 0.058
-
Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma. J Neurooncol. 2021 May; 152(3):515-522.
Score: 0.058
-
Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma. Sci Rep. 2021 01 27; 11(1):2306.
Score: 0.057
-
Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. Neuro Oncol. 2020 11 26; 22(11):1568-1579.
Score: 0.057
-
Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol. 2020; 4.
Score: 0.055
-
Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523.
Score: 0.054
-
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer. 2020 06 15; 126(12):2821-2828.
Score: 0.054
-
Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 2019 Nov; 80:101896.
Score: 0.052
-
Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Sci Transl Med. 2019 08 14; 11(505).
Score: 0.052
-
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019 03; 25(3):477-486.
Score: 0.050
-
Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy. AJR Am J Roentgenol. 2018 12; 211(6):1342-1347.
Score: 0.049
-
Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro Oncol. 2018 09 03; 20(10):1411-1418.
Score: 0.049
-
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 08 02; 20(9):1240-1250.
Score: 0.048
-
Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas. Neuro Oncol. 2018 08 02; 20(9):1262-1271.
Score: 0.048
-
Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro Oncol. 2018 01 22; 20(2):225-235.
Score: 0.047
-
Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2017 Nov 29; 19(12):1688-1697.
Score: 0.046
-
Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. J Neurooncol. 2017 Dec; 135(3):581-591.
Score: 0.046
-
Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545.
Score: 0.044
-
Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Crit Rev Oncol Hematol. 2017 Mar; 111:60-65.
Score: 0.043
-
Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol. 2017 01; 19(1):109-117.
Score: 0.042
-
MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. Oncotarget. 2016 Jun 14; 7(24):37054-37063.
Score: 0.042
-
Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab. Neuro Oncol. 2016 12; 18(12):1680-1687.
Score: 0.041
-
Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol. 2016 Jul-Aug; 6(4):217-225.
Score: 0.041
-
Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016 05; 18(5):649-55.
Score: 0.041
-
A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016 Feb; 18(2):269-74.
Score: 0.039
-
Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer. 2015 Dec 15; 121(24):4376-81.
Score: 0.039
-
Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol. 2015 Aug; 1(5):662-7.
Score: 0.039
-
Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation. J Neurooncol. 2015 Aug; 124(1):137-46.
Score: 0.039
-
Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):384-9.
Score: 0.038
-
Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55.
Score: 0.038
-
Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget. 2014 Sep 30; 5(18):8083-92.
Score: 0.037
-
Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Neuro Oncol. 2014 Nov; 16(11):1523-9.
Score: 0.036
-
Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro Oncol. 2014 Nov; 16(11):1547-53.
Score: 0.036
-
Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. J Neurooncol. 2014 Aug; 119(1):149-58.
Score: 0.036
-
Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. Neuro Oncol. 2013 Aug; 15(8):972-8.
Score: 0.034
-
PCV for anaplastic oligodendrogliomas: back to the future or a step backwards? A point/counterpoint discussion. J Neurooncol. 2013 May; 113(1):143-7.
Score: 0.033
-
Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma. 2013 Jan; 54(1):58-61.
Score: 0.032
-
Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 2012 May; 13(5):e196-204.
Score: 0.031
-
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012 May; 2(5):458-71.
Score: 0.031
-
Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) study 05-01. J Clin Oncol. 2011 May 20; 29(15_suppl):2039.
Score: 0.029
-
Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011 Jun; 12(6):583-93.
Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.